Subclinical Cardiovascular Disease in Psoriatic Disease

• Status: Completed
• Trial end date: 2019-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will look at how chronic inflammation seen in psoriatic disease translates into the increased atherosclerotic and thrombotic risk and how treatment reduces this CVD risk. The Aim of this study is to 1) Evaluate the association between moderate to severe psoriatic disease and measures of vascular function. 2) Evaluate the association between moderate to severe psoriatic disease and measures of thrombotic risk. 3) Understand how traditional medications used in cardiovascular disease (CVD) prevention such as aspirin and statins affect vascular function and thrombotic risk in those with moderate to severe psoriatic disease.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: New York University School of Medicine; NYU Langone Health
• Treatments: Aspirin; Atorvastatin; Atorvastatin Calcium

Criteria

Inclusion Criteria:

• Subjects with a history of moderate to severe psoriatic disease

• Group 2: Healthy subjects without known psoriatic disease or cardiovascular disease

Exclusion Criteria:

• Unable to speak Spanish or English

• Active smoking (within the past year)

• Autoimmune, rheumatologic or inflammatory disease which are not psoriasis or psoriatic arthritis

• Known active cancer receiving treatment

• Pregnancy

• Anemia (hemoglobin < 9 mg/dl) or thrombocytopenia (Platelet count <75), or thrombocytosis (Platelet count >600)

• A history of severe bleeding or bleeding disorders

• Current medication use which interact with either aspirin or atorvastatin

• Chronic kidney disease (CrCl < 30ml/min)

• Congestive heart failure

• Currently taking aspirin or a statin.

• NSAID use within the past 48 hours